Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

This study is testing a new type of CAR-T cell therapy called HBI0101 in people with multiple myeloma (a blood cancer) that has come back or stopped responding to previous treatments. CAR-T therapy re-engineers a patient's own immune cells to find and destroy cancer cells. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory multiple myeloma with measurable disease - You have received at least three prior lines of treatment, including a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody - You have had a stem cell transplant or are not eligible for one **You may NOT be eligible if...** - Your myeloma has spread to the brain or spinal cord - You have an active serious infection - You have had prior CAR-T therapy targeting BCMA - Your organ function or blood counts do not meet the required levels Talk to your doctor to see if this trial is right for you.